|By Marketwired .||
|August 5, 2014 07:03 AM EDT||
BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - August 05, 2014) - Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's second quarter 2014 financial results and provide an operational update on Thursday, August 7, at 4:30 p.m. ET. The conference call will follow the anticipated release of the company's second quarter 2014 financial results earlier that day.
The conference call can be heard live via the investor relations section of the company's website at www.amarincorp.com, or via telephone by dialing 877-407-8033 within the United States or 201-689-8033 from outside the United States. A replay of the call will be made available for a period of two weeks following the conference call. To hear a replay of the call, dial 877-660-6853 (inside the United States) or 201-612-7415 (outside the United States). A replay of the call will also be available through the company's website shortly after the call. For both dial-in numbers please use conference ID 13586651.
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl), Amarin's first FDA approved product, is an ultra-pure, EPA-only, omega-3 fatty acid product available by prescription. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.
Availability of other information about Amarin
Investors and others should note that we communicate with our investors and the public using our company website (www.amarincorp.com), our investor relations website (http://www.amarincorp.com/investor-splash.html), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in Amarin to review the information that we post on these channels, including our investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
DevOps tends to focus on the relationship between Dev and Ops, putting an emphasis on the ops and application infrastructure. But that’s changing with microservices architectures. In her session at DevOps Summit, Lori MacVittie, Evangelist for F5 Networks, will focus on how microservices are changing the underlying architectures needed to scale, secure and deliver applications based on highly distributed (micro) services and why that means an expansion into “the network” for DevOps.
Jul. 8, 2015 04:00 AM EDT Reads: 3,183
Jul. 8, 2015 03:00 AM EDT Reads: 880
Jul. 8, 2015 03:00 AM EDT Reads: 1,656
Jul. 8, 2015 02:15 AM EDT Reads: 1,157
Jul. 8, 2015 12:00 AM EDT Reads: 2,553
Jul. 7, 2015 10:30 PM EDT Reads: 2,508
Jul. 7, 2015 10:15 PM EDT Reads: 1,277
Jul. 7, 2015 09:30 PM EDT Reads: 1,278
Jul. 7, 2015 08:00 PM EDT Reads: 1,039
Jul. 7, 2015 07:00 PM EDT Reads: 2,648
Jul. 7, 2015 07:00 PM EDT Reads: 2,675
Jul. 7, 2015 05:45 PM EDT Reads: 2,518
Jul. 7, 2015 05:00 PM EDT Reads: 2,338
Jul. 7, 2015 05:00 PM EDT Reads: 2,295
Jul. 7, 2015 04:45 PM EDT Reads: 1,764